@article{oai:mie-u.repo.nii.ac.jp:00008102,
 author = {宮澤, 憲治 and Miyazawa, Kenji and 世古口, 典子 and Sekoguchi, Noriko and 岩本, 卓也 and Iwamoto, Takuya and 村木, 優一 and Muraki, Yuichi and 田中, 秀明 and Tanaka, Hideaki and 岩佐, 元雄 and Iwasa, Motoh and 山門, 享一郎 and Yamakado, Kouichiro and 竹田, 寛 and Takeda, Kan and 竹井, 謙之 and Takei, Yoshiyuki and 奥田, 真弘 and Okuda, Masahiro},
 issue = {8},
 journal = {医療薬学},
 month = {Aug},
 note = {application/pdf, Transcatheter arterial embolization (TAB) and transcatheter arterial infusion (TAI) using cisplatin suspended in Lipiodol® Ultra-Fluide (Cisplatin/Lipiodol) are considered to be useful tumor-targeting therapies for hepatocellular carcinoma. However, little information is available on adverse events due to injection of Cisplatin/Lipiodol because the combined use Lipiodol and Cisplatin has not been approved by the Japanese government yet. Upon investigating the frequency and time of onset of adverse events following injection of Cisplatin/Lipiodol in 16 in-patients at Mie University Hospital, the frequency of the subjective symptoms of stomachache including epigastrium ache (75.0%), nausea or vomiting (50.0%), fever (50.0%), and gastric region discomfort (37.5%) was observed to be high. Further, leucocytes and neutrophils increased 2 days after injection (p< 0.001) and the onset of thrombocytopenia was much earlier than that following injection of Cisplatin alone. Severe adverse events defined as grade 3 or 4 in the Common Toxicity Criteria for Adverse Events Version 3.0 (JCOG/JSCO version, National Cancer Institute) were observed in 12 patients. These results suggest that great caution should be exercised with respect to adverse events occurring during Cisplatin/Lipiodol therapy.},
 pages = {794--799},
 title = {原発性肝がんに対するシスプラチン・リピオドール療法時の有害事象調査},
 volume = {34},
 year = {2008}
}